The impact of dose reduction on survival for colon cancer patients treated with adjuvant FOLFOX

Authors :: Jacob C. Easaw
Fahad Ibnshamsah
Source :: Journal of Clinical Oncology. 32:e14576-e14576
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: e14576 Background: Dose reduction (DR) is common during oxaliplatin based treatment for stage III colon cancer. In this study we evaluated the impact of DR of adjuvant FOLFOX chemotherapy on diseas...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Chemotherapy
business.industry
Colorectal cancer
medicine.medical_treatment
medicine.disease
digestive system diseases
Oxaliplatin
Stage III Colon Cancer
FOLFOX
Internal medicine
Medicine
Dose reduction
business
Adjuvant
medicine.drug

Tools